The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report

Dr. Elemer Piros (09/30/2022)

Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial

Streetwise Reports (09/30/2022)

Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial

Streetwise Reports (09/29/2022)

Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease.

Tags: Biotechnology / Pharmaceuticals

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report

Edward White (09/29/2022)

The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Oncology Co.'s Shares Erupt on Signing Global License Deal

Streetwise Reports (09/27/2022)

Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors.

Tags: Biotechnology / Pharmaceuticals

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report

Dr. Joseph Pantginis (09/23/2022)

To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report

Dr. David Nierengarten (09/23/2022)

Argenx SE has "several upcoming catalysts," noted a Wedbush report.

Tags: Special SituationsBiotechnology / Pharmaceuticals

FDA Approves Hearing Loss Drug for Child Chemo Patients

Streetwise Reports (09/21/2022)

Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors.

Tags: Biotechnology / Pharmaceuticals

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report

Dr. David Nierengarten (09/20/2022)

The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Dermatology Co.'s Target Price Much Higher Than Current

Research Report

Dr. Jonathan Aschoff (09/20/2022)

The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data

Streetwise Reports (09/20/2022)

Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23.

Tags: Biotechnology / Pharmaceuticals

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report

Dr. Yi Chen (09/17/2022)

The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

FDA Grants Approval for Drug Improving Kidney Function

Streetwise Reports (09/16/2022)

Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function.

Tags: Biotechnology / Pharmaceuticals

Price Target on US Biopharma Co. Boosted by $15

Research Report

Julian Harrison (09/15/2022)

The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

New Drug Shown To Help Patients With Desmoid Tumors

Research Report

Dr. David Nierengarten (09/15/2022)

This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Co. Advancing Drug Class With Broad Potential

Research Report

Dr. Thomas Shrader (09/13/2022)

This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion

Clive Maund (09/13/2022)

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

Streetwise Reports (09/12/2022)

One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report

Dr. Jonathan Aschoff (09/12/2022)

Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Receives Approval From FDA Panel for ALS Drug

Streetwise Reports (09/08/2022)

Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022.

Tags: Biotechnology / Pharmaceuticals

Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials

Streetwise Reports (09/08/2022)

Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients.

Tags: Medical DevicesBiotechnology / Pharmaceuticals

US Co. To Regain All Rights to Its AGHD Diagnostic Test

Research Report

Dr. Ram Selvaraju (09/08/2022)

This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.

Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Biopharma Co. Transforming Injected Drugs Into Pills

Research Report

Dr. Ram Selvaraju (09/07/2022)

This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it.

Tags: Biotechnology / Pharmaceuticals

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Contributed Opinion

Clive Maund (09/07/2022)

Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Two Talks On New Cancer Drug Slated for Meeting This Week

Research Report

Dr. Tony Butler (09/06/2022)

The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 145 Next